Table 1 Demographic and clinical characteristics of patients prior to bosutinib therapy.
Female:male | 13:15 | |
Age (years) | 55 ± 16 | (22–80) |
Body weight (kg) | 64 ± 16 | (44–101) |
Bosutinib therapy | ||
First-line:second-line or later | 8:20 | |
Medical history | ||
Diabetes (yes:no) | 3:25 | |
Hypertension (yes:no) | 7:21 | |
Laboratory test values | ||
White blood cells (× 103/mm3) | 16.0 ± 7 | (1–77.7) |
Platelets (× 104/mm3) | 41.5 ± 62.6 | (12.1–326) |
Aspartate transaminase (IU/L) | 24 ± 9 | (10–56) |
Alanine transaminase (IU/L) | 25 ± 16 | (7–83) |
Serum albumin (g/dL) | 4.2 ± 0.4 | (3.0–4.8) |
Total bilirubin (mg/dL) | 0.7 ± 0.5 | (0.3–2.7) |
Serum creatinine (mg/dL) | 0.69 ± 0.19 | (0.42–1.04) |
eGFR (mL/min/1.73 m2) | 86.0 ± 19.7 | (50.2–122) |
